Boehringer Ingelheim presents strong lung cancer portfolio and long-awaited

A-A+
睿商网 文传商讯

Boehringer Ingelheim presents strong lung cancer portfolio and long-awaited head-to-head data of afatinib compared to gefitinib at ESMO Asia 2015 Congress 

  本文链接:http://www.iruis.com/News/cninfo/39581.shtml